View Item 

Show simple item record

Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial †
dc.contributor.authorAdamopoulos, Chrisen_US
dc.contributor.authorAhmed, Alien_US
dc.contributor.authorFay, Renauden_US
dc.contributor.authorAngioi, Michaelen_US
dc.contributor.authorFilippatos, Gerasimosen_US
dc.contributor.authorVincent, Johnen_US
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorZannad, Faiezen_US
dc.date.accessioned2014-02-11T17:57:24Z
dc.date.available2014-02-11T17:57:24Z
dc.date.issued2009-11en_US
dc.identifier.citationAdamopoulos, Chris; Ahmed, Ali; Fay, Renaud; Angioi, Michael; Filippatos, Gerasimos; Vincent, John; Pitt, Bertram; Zannad, Faiez (2009). "Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial † ." European Journal of Heart Failure 11(11): 1099-1105. <http://hdl.handle.net/2027.42/102721>en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/102721
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherAldosterone Antagonistsen_US
dc.subject.otherHeart Failureen_US
dc.subject.otherMortalityen_US
dc.subject.otherVentricular Remodellingen_US
dc.subject.otherMyocardial Infarctionen_US
dc.titleTiming of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial †en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid19875410en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/102721/1/ejhfhfp136.pdf
dc.identifier.doi10.1093/eurjhf/hfp136en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferenceRogers WJ Bourge RC Papapietro SE Wackers FJ Zaret BL Forman S Dodge HT Robertson TL Passamani ER Braunwald E for the TIMI Investigators Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study Am J Cardiol 1989 63 503 512en_US
dc.identifier.citedreferencePitt B Remme W Zannad F Neaton J Martinez F Roniker B Bittman R Hurley S Kleiman J Gatlin M Eplerenone a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 348 1309 1321en_US
dc.identifier.citedreferencePitt B Williams G Remme W Martinez F Lopez‐Sendon J Zannad F Neaton J Roniker B Hurley S Burns D Bittman R Kleiman J The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study Cardiovasc Drugs Ther 2001 15 79 87en_US
dc.identifier.citedreferencePerrier E Kerfant BG Lalevee N Bideaux P Rossier MF Richard S Gomez AM Benitah JP Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction Circulation 2004 110 776 783en_US
dc.identifier.citedreferenceWard MR Kanellakis P Ramsey D Funder J Bobik A Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries Circulation 2001 104 467 472en_US
dc.identifier.citedreferenceChun TY Pratt JH Aldosterone increases plasminogen activator inhibitor‐1 synthesis in rat cardiomyocytes Mol Cell Endocrinol 2005 239 55 61en_US
dc.identifier.citedreferenceSawathiparnich P Kumar S Vaughan DE Brown NJ Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor‐1 in humans J Clin Endocrinol Metab 2002 87 448 452en_US
dc.identifier.citedreferenceSawathiparnich P Murphey LJ Kumar S Vaughan DE Brown NJ Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor‐1 J Clin Endocrinol Metab 2003 88 3867 3873en_US
dc.identifier.citedreferenceFraccarollo D Galuppo P Schraut S Kneitz S van Rooijen N Ertl G Bauersachs J Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response Hypertension 2008 51 905 914en_US
dc.identifier.citedreferenceHasdai D Topol EJ Kilaru R Battler A Harrington RA Vahanian A Ohman EM Granger CB Van de Werf F Simoons ML O'Connor CM Holmes DR Jr Frequency, patient characteristics, and outcomes of mild‐to‐moderate heart failure complicating ST‐segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials Am Heart J 2003 145 73 79en_US
dc.identifier.citedreferenceSteg PG Dabbous OH Feldman LJ Cohen‐Solal A Aumont MC Lopez‐Sendon J Budaj A Goldberg RJ Klein W Anderson FA Jr Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE) Circulation 2004 109 494 499en_US
dc.identifier.citedreferenceVelazquez EJ Francis GS Armstrong PW Aylward PE Diaz R O'Connor CM White HD Henis M Rittenhouse LM Kilaru R van Gilst W Ertl G Maggioni AP Spac J Weaver WD Rouleau JL McMurray JJ Pfeffer MA Califf RM An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry Eur Heart J 2004 25 1911 1919en_US
dc.identifier.citedreferenceWu AH Parsons L Every NR Bates ER Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI‐2) J Am Coll Cardiol 2002 40 1389 1394en_US
dc.identifier.citedreferenceGruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico GISSI‐3: effects of lisinopril transdermal glyceryl trinitrate singly together on 6‐week mortality ventricular function after acute myocardial infarction Lancet 1994 343 1115 1122en_US
dc.identifier.citedreferenceAmbrosioni E Borghi C Magnani B The Survival of Myocardial Infarction Long‐Term Evaluation (SMILE) Study Investigators The effect of the angiotensin‐converting‐enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction N Engl J Med 1995 332 80 85en_US
dc.identifier.citedreferenceFonarow GC Gawlinski A Moughrabi S Tillisch JH Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) Am J Cardiol 2001 87 819 822en_US
dc.identifier.citedreferenceRodrigues EJ Eisenberg MJ Pilote L Effects of early and late administration of angiotensin‐converting enzyme inhibitors on mortality after myocardial infarction Am J Med 2003 115 473 479en_US
dc.identifier.citedreferencePitt B White H Nicolau J Martinez F Gheorghiade M Aschermann M van Veldhuisen DJ Zannad F Krum H Mukherjee R Vincent J Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure J Am Coll Cardiol 2005 46 425 431en_US
dc.identifier.citedreferenceSolomon SD Zelenkofske S McMurray JJ Finn PV Velazquez E Ertl G Harsanyi A Rouleau JL Maggioni A Kober L White H Van de Werf F Pieper K Califf RM Pfeffer MA Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both N Engl J Med 2005 352 2581 2588en_US
dc.identifier.citedreferenceHohnloser SH Kuck KH Dorian P Roberts RS Hampton JR Hatala R Fain E Gent M Connolly SJ Prophylactic use of an implantable cardioverter‐defibrillator after acute myocardial infarction N Engl J Med 2004 351 2481 2488en_US
dc.identifier.citedreferenceMasoudi FA Havranek EP Wolfe P Gross CP Rathore SS Steiner JF Ordin DL Krumholz HM Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure Am Heart J 2003 146 250 257en_US
dc.identifier.citedreferenceButler J Arbogast PG BeLue R Daugherty J Jain MK Ray WA Griffin MR Outpatient adherence to beta‐blocker therapy after acute myocardial infarction J Am Coll Cardiol 2002 40 1589 1595en_US
dc.identifier.citedreferenceButler J Arbogast PG Daugherty J Jain MK Ray WA Griffin MR Outpatient utilization of angiotensin‐converting enzyme inhibitors among heart failure patients after hospital discharge J Am Coll Cardiol 2004 43 2036 2043en_US
dc.identifier.citedreferencePitt B Zannad F Remme WJ Cody R Castaigne A Perez A Palensky J Wittes J Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 1999 341 709 717en_US
dc.identifier.citedreferenceDelyani JA Robinson EL Rudolph AE Effect of a selective aldosterone receptor antagonist in myocardial infarction Am J Physiol Heart Circ Physiol 2001 281 H647 H654en_US
dc.identifier.citedreferenceBeygui F Collet JP Benoliel JJ Vignolles N Dumaine R Barthelemy O Montalescot G High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST‐elevation myocardial infarction Circulation 2006 114 2604 2610en_US
dc.identifier.citedreferenceHayashi M Tsutamoto T Wada A Maeda K Mabuchi N Tsutsui T Matsui T Fujii M Matsumoto T Yamamoto T Horie H Ohnishi M Kinoshita M Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction J Am Coll Cardiol 2001 38 1375 1382en_US
dc.identifier.citedreferencePalmer BR Pilbrow AP Frampton CM Yandle TG Skelton L Nicholls MG Richards AM Plasma aldosterone levels during hospitalization are predictive of survival post‐myocardial infarction Eur Heart J 2008 29 2489 2496en_US
dc.identifier.citedreferenceHayashi M Tsutamoto T Wada A Tsutsui T Ishii C Ohno K Fujii M Taniguchi A Hamatani T Nozato Y Kataoka K Morigami N Ohnishi M Kinoshita M Horie M Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post‐infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 2003 107 2559 2565en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhfhfp136.pdf
Size:
190.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.